EnCor Biotechnology encorbio.com


EnCor Biotechnology Inc., of Gainesville, Florida is a maker of high quality antibodies to neural and yeast proteins

EnCor Biotechnology Inc., of Gainesville, Florida is a maker of high quality antibodies to neural and yeast proteins

Company (Alive / Active)

Phone: 352-372-7022

Fax: 352-372-7066

Interstate Office Park, 4949 SW 41st Boulevard
Suite 40
Gainesville, 32608
Florida, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
EnCor Biotechnology $0M Nov 30, 2018
See all 16 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related EnCor Biotechnology Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

RAVEN Biotechnologies

South San Francisco, California, United States
AcquiredRaven biotechnologies is a privately held biotechnology company focused on the simultaneous discovery of novel cell surface drug targets and the antibody therapeutics to regulate them. Raven's integrated approach is based on proprietary, human tissue-specific progenitor and tumor cell lines developed at Raven, plus proprietary methods optimized for producing monoclonal antibodies (MAbs) targeting cell surface proteins. This platform rapidly identifies target antigens and therapeutic candidates i...Show allLogin to see details

Taligen Therapeutics

Cambridge, Massachusetts, United States
AcquiredTaligen Therapeutics is a development-stage biotechnology company. In January 2011, Taligen Therapeutics was acquired by Alexion Pharmaceuticals. The valuation of Taligen Therapeutics was $111 million.Login to see details
See all 16 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)